Efficacy News and Research

RSS

New valve repair device that could replace major heart surgery

The Hospital of the University of Pennsylvania (HUP) is participating in a nationwide clinical trial of a new valve repair device that could replace major heart surgery in some patients.

8 Nov 2004

Patent granted for novel collagen delivery system

Hydroderm announced today that after years of clinical research, Hydroderm's exclusive Collagen Infusion Delivery System was granted a U.S. patent.

8 Nov 2004

Antidepressants may help people quit smoking when used in conjunction with nicotine patches

When used with a transdermal nicotine patch, nortriptyline—an antidepressant medication—may aid in smoking cessation, according to an article in the November 8 issue of The Archives of Internal Medicine, one of the JAMA/Archives journals.

8 Nov 2004

Lipid Sciences' selective delipidation process demonstrates enhanced ability in removing cholesterol from cells

Lipid Sciences announced today that researchers have successfully used the Company's proprietary "selective delipidation" process to create a modified form of HDL ("good cholesterol") that is known to be more effective in reverse cholesterol transport, the body's natural process for removing lipids from arterial plaque.

8 Nov 2004

Link between immune protein and longer survival in melanoma patients

Immune responses to prevent or delay the spread of melanoma, a deadly form of skin cancer, are more likely to prolong survival in patients if their immune cells carry a special kind of marker on the surface, according to a team of researchers at the University of Virginia Health System.

5 Nov 2004

Treatment to control gastroesophageal reflux disease in children found to be ineffective

According to a study published in the American Gastroenterological Association (AGA) journal Clinical Gastroenterology and Hepatology, more than 60 percent of the children who received surgical fundoplication to control gastroesophageal reflux disease (GERD) had recurring symptoms of the disease months following surgery.

4 Nov 2004

Cyclooxygenase (COX) inhibitors tested in both prevention and treatment clinical trials

Numerous compounds are examined by the National Cancer Institute (NCI) for their potential to prevent or treat cancer. One class of compounds, cyclooxygenase (COX) inhibitors, is currently being tested in both prevention and treatment clinical trials.

4 Nov 2004

Psoriasis trial enters final stage

Solbec Pharmaceuticals Ltd today announced the successful completion of the first two stages of the Phase I clinical trial of its lead compound, CoramsineTM (SBP002), for the treatment of psoriasis.

4 Nov 2004

Mad cow disease prions can be removed from blood

New research results released today confirm that infectious variant Creutzfeldt-Jakob Disease (vCJD) prions that cause the human form of "mad cow disease" can be removed from blood.

From Pall Corporation 3 Nov 2004

Studies show Pfizer's Azithromycin Microspheres effective as treatment for respiratory tract infections

Pfizer Inc.'s new investigational microsphere formulation of azithromycin, which is dosed as a one-time-only oral antibiotic, is comparable to other frequently prescribed treatments for some of the most common respiratory tract infections in adult patients.

1 Nov 2004

No evidence that Glatiramer acetate slows multiple sclerosis progression

In this week's issue of the Lancet Neurology, glatiramer acetate, known as Copaxone(R), was subjected to an independent review. The systematic review, called a Cochrane Review, performed by Dr. Luca Munari and colleagues, challenges the claims of benefit from previous industry- based publications.

1 Nov 2004

Sport program reduced eating disordered behavior and body-shaping drug use in female high school athletes

A peer-led, sport team-centered program reduces eating disordered behavior and body-shaping drug use in female high school athletes, according to an article in the November issue of The Archives of Pediatrics & Adolescent Medicine.

1 Nov 2004

Pegasys with ribavirin combo may best for reducing hepatitis C viral levels

Interim study results indicate a certain drug combination treatment may suppress the hepatitis C virus more quickly than another.

1 Nov 2004

Gel significantly increases sexual activity in surgically menopausal women

BioSante Pharmaceuticals today announced the presentation of new Phase II clinical data on LibiGel™ (transdermal testosterone gel) at the International Society for the Study of Women's Sexual Health (ISSWSH) Annual Meeting in Atlanta.

1 Nov 2004

Uterine fibroid treatment option 'safe and effective'

Boston Scientific Corporation today welcomed an announcement by the Interventional Procedures Advisory Committee (IPAC) of the National Institute for Clinical Excellence (NICE), confirming the safety and efficacy of uterine fibroid embolization (UFE), an innovative treatment for fibroids.

1 Nov 2004

Gastric acid-suppressive medications may increase risk of developing pneumonia

Individuals who use gastric acid-suppressive medications may be at an elevated risk of developing community-acquired pneumonia, according to an article in the October 27 issue of JAMA.

28 Oct 2004

Project to refine and fine-tune radiotherapy treatment for cancer

The EU-funded GENEPI project will provide the facility for essential research which will improve and refine radiotherapy for European cancer patients

26 Oct 2004

Researchers are comparing two drugs used to treat pediatric bipolar disorder

University of Illinois at Chicago researchers are comparing two drugs used to treat pediatric bipolar disorder patients to evaluate how the drugs affect brain function in children with the disorder.

25 Oct 2004

Breakthrough discovery in treating narrowed arteries

A breakthrough discovery by Heart and Stroke Foundation researcher Dr. Michael Kutryk that harnesses the body’s own natural defenses to fight narrowing of the arteries has been recognized as “a glimpse into the future” and “potentially one of the biggest advances in cardiology to date”.

25 Oct 2004

Boehringer Ingelheim - New Drug Application (NDA) for tipranavir

The Company is seeking accelerated approval of tipranavir and has requested a priority, six-month review of the NDA. Priority review designation is based upon whether a drug provides a significant improvement in the treatment of a serious or life-threatening disease.

25 Oct 2004